A carregar...
Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway.
Cisplatin has been the most accepted drug for the treatment of ovarian cancer for almost 40 years. Although the majority of patients with ovarian cancer respond to front-line platinum combination chemotherapy, many patients will develop cisplatin-resistance disease, which is extremely rapid and fata...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science (PLoS)
2014-01-01
|
| Colecção: | PLoS ONE |
| Acesso em linha: | http://europepmc.org/articles/PMC4035252?pdf=render |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|